|
1
|
Christ M, Störk S, Dörr M, Heppner HJ,
Müller C, Wachter R and Riemer U: Trend HF Germany Project. Heart
failure epidemiology 2000-2013: Insights from the German federal
health monitoring system. Eur J Heart Fail. 18:1009–1018.
2016.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
DeSantis CE, Siegel RL, Sauer AG, Miller
KD, Fedewa SA, Alcaraz KI and Jemal A: Cancer statistics for
African Americans, 2016: Progress and opportunities in reducing
racial disparities. CA Cancer J Clin. 66:290–308. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Armenian SH, Xu L, Ky B, Sun C, Farol LT,
Pal SK, Douglas PS, Bhatia S and Chao C: Cardiovascular disease
among survivors of adult-onset cancer: A community-based
retrospective cohort study. J Clin Oncol. 34:1122–1130.
2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Choi HM, Park MS and Youn JC: Update on
heart failure management and future directions. Korean J Intern
Med. 34:11–43. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Swain SM, Whaley FS and Ewer MS:
Congestive heart failure in patients treated with doxorubicin: A
retrospective analysis of three trials. Cancer. 97:2869–2879.
2003.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Saiki H, Petersen IA, Scott CG, Bailey KR,
Dunlay SM, Finley RR, Ruddy KJ, Yan E and Redfield MM: Risk of
heart failure with preserved ejection fraction in older women after
contemporary radiotherapy for breast cancer. Circulation.
135:1388–1396. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Quarta CC, Solomon SD, Uraizee I, Kruger
J, Longhi S, Ferlito M, Gagliardi C, Milandri A, Rapezzi C and Falk
RH: Left ventricular structure and function in
transthyretin-related versus light-chain cardiac amyloidosis.
Circulation. 129:1840–1849. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
van Nimwegen FA, Schaapveld M, Janus CP,
Krol AD, Petersen EJ, Raemaekers JM, Kok WE, Aleman BM and van
Leeuwen FE: Cardiovascular disease after Hodgkin lymphoma
treatment: 40-year disease risk. JAMA Intern Med. 175:1007–1017.
2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Laufer-Perl M, Mor L, Milwidsky A,
Derakhshesh M, Amrami N, Moshkovits Y, Arnold J, Topilsky Y, Arbel
Y and Rozenbaum Z: Cancer therapeutics-related cardiac dysfunction
among patients with active breast cancer: A cardio-oncology
registry. Isr Med Assoc J. 22:564–568. 2020.PubMed/NCBI
|
|
11
|
Tian Z, Yang Y, Yang Y, Zhang F, Li P,
Wang J, Yang J, Zhang P, Yao W and Wang X: High cumulative
doxorubicin dose for advanced soft tissue sarcoma. BMC Cancer.
20(1139)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Degens J, De Ruysscher D, Houben R,
Kietselaer B, Bootsma G, Hendriks L, Huijbers E, Schols A and
Dingemans AC: Are patients with stage III non-small cell lung
cancer treated with chemoradiotherapy at risk for cardiac events?
Results from a retrospective cohort study. BMJ Open.
10(e036492)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kjekshus J, Apetrei E, Barrios V, Böhm M,
Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P,
et al: Rosuvastatin in older patients with systolic heart failure.
N Engl J Med. 357:2248–2261. 2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Linde C, Abraham WT, Gold MR, St John
Sutton M, Ghio S and Daubert C: REVERSE (REsynchronization reVErses
Remodeling in Systolic left vEntricular dysfunction) Study Group.
Randomized trial of cardiac resynchronization in mildly symptomatic
heart failure patients and in asymptomatic patients with left
ventricular dysfunction and previous heart failure symptoms. J Am
Coll Cardiol. 52:1834–1843. 2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Moss AJ, Hall WJ, Cannom DS, Klein H,
Brown MW, Daubert JP, Estes NA III, Foster E, Greenberg H, Higgins
SL, et al: Cardiac-resynchronization therapy for the prevention of
heart-failure events. N Engl J Med. 361:1329–1338. 2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ruschitzka F, Abraham WT, Singh JP, Bax
JJ, Borer JS, Brugada J, Dickstein K, Ford I, Gorcsan J III, Gras
D, et al: Cardiac-resynchronization therapy in heart failure with a
narrow QRS complex. N Engl J Med. 369:1395–1405. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
McMurray JJ, Packer M, Desai AS, Gong J,
Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg
K, et al: Angiotensin-neprilysin inhibition versus enalapril in
heart failure. N Engl J Med. 371:993–1004. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Doval HC, Nul DR, Grancelli HO, Perrone
SV, Bortman GR and Curiel R: Randomised trial of low-dose
amiodarone in severe congestive heart failure. Grupo de Estudio de
la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA).
Lancet. 344:493–498. 1994.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bigger JT Jr: Prophylactic use of
implanted cardiac defibrillators in patients at high risk for
ventricular arrhythmias after coronary-artery bypass graft surgery.
Coronary artery bypass graft (CABG) patch trial investigators. N
Engl J Med. 337:1569–1575. 1997.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kadish A, Dyer A, Daubert JP, Quigg R,
Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A,
et al: Prophylactic defibrillator implantation in patients with
nonischemic dilated cardiomyopathy. N Engl J Med. 350:2151–2158.
2004.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Granger CB, McMurray JJ, Yusuf S, Held P,
Michelson EL, Olofsson B, Ostergren J, Pfeffer MA and Swedberg K:
CHARM Investigators and Committees. Effects of candesartan in
patients with chronic heart failure and reduced left-ventricular
systolic function intolerant to angiotensin-converting-enzyme
inhibitors: The CHARM-alternative trial. Lancet. 362:772–776.
2003.PubMed/NCBI View Article : Google Scholar
|
|
22
|
McMurray JJ, Ostergren J, Swedberg K,
Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S and Pfeffer
MA: CHARM Investigators and Committees. Effects of candesartan in
patients with chronic heart failure and reduced left-ventricular
systolic function taking angiotensin-converting-enzyme inhibitors:
The CHARM-added trial. Lancet. 362:767–771. 2003.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Roy D, Talajic M, Nattel S, Wyse DG,
Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, et
al: Rhythm control versus rate control for atrial fibrillation and
heart failure. N Engl J Med. 358:2667–2677. 2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tavazzi L, Maggioni AP, Marchioli R,
Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M and
Tognoni G: Gissi-HF Investigators. Effect of n-3 polyunsaturated
fatty acids in patients with chronic heart failure (the GISSI-HF
trial): A randomised, double-blind, placebo-controlled trial.
Lancet. 372:1223–1230. 2008.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Velazquez EJ, Lee KL, Deja MA, Jain A,
Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, et
al: Coronary-artery bypass surgery in patients with left
ventricular dysfunction. N Engl J Med. 364:1607–1616.
2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bertero E, Canepa M, Maack C and Ameri P:
Linking heart failure to cancer: Background evidence and research
perspectives. Circulation. 138:735–742. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Meijers WC, Maglione M, Bakker SJL,
Oberhuber R, Kieneker LM, de Jong S, Haubner BJ, Nagengast WB, Lyon
AR, van der Vegt B, et al: Heart failure stimulates tumor growth by
circulating factors. Circulation. 138:678–691. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Bertero E, Ameri P and Maack C:
Bidirectional relationship between cancer and heart failure: Old
and new issues in cardio-oncology. Card Fail Rev. 5:106–111.
2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ausoni S and Azzarello G: Development of
cancer in patients with heart failure: How systemic inflammation
can lay the groundwork. Front Cardiovasc Med.
7(598384)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tan C, Tasaka H, Yu KP, Murphy ML and
Karnofsky DA: Daunomycin, an antitumor antibiotic, in the treatment
of neoplastic disease. Clinical evaluation with special reference
to childhood leukemia. Cancer. 20:333–353. 1967.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Vandecruys E, Mondelaers V, De Wolf D,
Benoit Y and Suys B: Late cardiotoxicity after low dose of
anthracycline therapy for acute lymphoblastic leukemia in
childhood. J Cancer Surviv. 6:95–101. 2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Frederick CA, Williams LD, Ughetto G, van
der Marel GA, van Boom JH, Rich A and Wang AH: Structural
comparison of anticancer drug-DNA complexes: Adriamycin and
daunomycin. Biochemistry. 29:2538–2549. 1990.PubMed/NCBI
|
|
33
|
Martin E, Thougaard AV, Grauslund M,
Jensen PB, Bjorkling F, Hasinoff BB, Tjørnelund J, Sehested M and
Jensen LH: Evaluation of the topoisomerase II-inactive
bisdioxopiperazine ICRF-161 as a protectant against
doxorubicin-induced cardiomyopathy. Toxicology. 255:72–79.
2009.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu
YL, Liu LF and Yeh ET: Identification of the molecular basis of
doxorubicin-induced cardiotoxicity. Nat Med. 18:1639–1642.
2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Jones RL: Utility of dexrazoxane for the
reduction of anthracycline-induced cardiotoxicity. Expert Rev
Cardiovasc Ther. 6:1311–1317. 2008.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hasinoff BB, Patel D and Wu X: The role of
topoisomerase IIβ in the mechanisms of action of the doxorubicin
cardioprotective agent dexrazoxane. Cardiovasc Toxicol. 20:312–320.
2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Abd El-Aziz MA, Othman AI, Amer M and
El-Missiry MA: Potential protective role of angiotensin-converting
enzyme inhibitors captopril and enalapril against
adriamycin-induced acute cardiac and hepatic toxicity in rats. J
Appl Toxicol. 21:469–473. 2001.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Li M, Sala V, De Santis MC, Cimino J,
Cappello P, Pianca N, Di Bona A, Margaria JP, Martini M, Lazzarini
E, et al: Phosphoinositide 3-kinase gamma inhibition protects from
anthracycline cardiotoxicity and reduces tumor growth. Circulation.
138:696–711. 2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Paris F, Fuks Z, Kang A, Capodieci P, Juan
G, Ehleiter D, Haimovitz-Friedman A, Cordon-Cardo C and Kolesnick
R: Endothelial apoptosis as the primary lesion initiating
intestinal radiation damage in mice. Science. 293:293–297.
2001.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Orzan F, Brusca A, Conte MR, Presbitero P
and Figliomeni MC: Severe coronary artery disease after radiation
therapy of the chest and mediastinum: Clinical presentation and
treatment. Br Heart J. 69:496–500. 1993.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Sag CM, Wolff HA, Neumann K, Opiela MK,
Zhang J, Steuer F, Sowa T, Gupta S, Schirmer M, Hünlich M, et al:
Ionizing radiation regulates cardiac Ca handling via increased ROS
and activated CaMKII. Basic Res Cardiol. 108(385)2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
De Keulenaer GW, Doggen K and Lemmens K:
The vulnerability of the heart as a pluricellular paracrine organ:
Lessons from unexpected triggers of heart failure in targeted ErbB2
anticancer therapy. Circ Res. 106:35–46. 2010.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Suter TM, Procter M, van Veldhuisen DJ,
Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin
C, Klijn JG, et al: Trastuzumab-associated cardiac adverse effects
in the herceptin adjuvant trial. J Clin Oncol. 25:3859–3865.
2007.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Bergers G and Benjamin LE: Tumorigenesis
and the angiogenic switch. Nat Rev Cancer. 3:401–410.
2003.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Carlsson L, Ronquist G, Elisasson R,
Dubois L, Ronquist KG and Larsson A: High concentrations of the
angiogenic peptide VEGF-A in seminal fluid and its association to
prostasomes. Clin Lab. 62:1515–1520. 2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Elice F, Jacoub J, Rickles FR, Falanga A
and Rodeghiero F: Hemostatic complications of angiogenesis
inhibitors in cancer patients. Am J Hematol. 83:862–270.
2008.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Cobleigh MA, Langmuir VK, Sledge GW,
Miller KD, Haney L, Novotny WF, Reimann JD and Vassel A: A phase
I/II dose-escalation trial of bevacizumab in previously treated
metastatic breast cancer. Semin Oncol. 30 (5 Suppl 16):S117–S124.
2003.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Kappers MH, van Esch JH, Sluiter W,
Sleijfer S, Danser AH and van den Meiracker AH: Hypertension
induced by the tyrosine kinase inhibitor sunitinib is associated
with increased circulating endothelin-1 levels. Hypertension.
56:675–681. 2010.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Li W, Croce K, Steensma DP, McDermott DF,
Ben-Yehuda O and Moslehi J: Vascular and metabolic implications of
novel targeted cancer therapies: Focus on kinase inhibitors. J Am
Coll Cardiol. 66:1160–1178. 2015.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Neves KB, Rios FJ, Jones R, Evans T,
Montezano AC and Touyz RM: Microparticles from vascular endothelial
growth factor pathway inhibitor-treated cancer patients mediate
endothelial cell injury. Cardiovasc Res. 115:978–988.
2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Maurea N, Coppola C, Piscopo G, Galletta
F, Riccio G, Esposito E, De Lorenzo C, De Laurentiis M, Spallarossa
P and Mercuro G: Pathophysiology of cardiotoxicity from target
therapy and angiogenesis inhibitors. J Cardiovasc Med (Hagerstown).
17 (Suppl 1):S19–S26. 2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Schmidinger M, Zielinski CC, Vogl UM,
Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M and Schmidinger H:
Cardiac toxicity of sunitinib and sorafenib in patients with
metastatic renal cell carcinoma. J Clin Oncol. 26:5204–5212.
2008.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Richardson PG, Sonneveld P, Schuster MW,
Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D,
Lonial S, Goldschmidt H, et al: Bortezomib or high-dose
dexamethasone for relapsed multiple myeloma. N Engl J Med.
352:2487–2498. 2005.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Waxman AJ, Clasen S, Hwang WT, Garfall A,
Vogl DT, Carver J, O'Quinn R, Cohen AD, Stadtmauer EA, Ky B and
Weiss BM: Carfilzomib-associated cardiovascular adverse events: A
systematic review and meta-analysis. JAMA Oncol.
4(e174519)2018.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Herrmann J, Wohlert C, Saguner AM, Flores
A, Nesbitt LL, Chade A, Lerman LO and Lerman A: Primary proteasome
inhibition results in cardiac dysfunction. Eur J Heart Fail.
15:614–623. 2013.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Vandenberg JI, Perry MD, Perrin MJ, Mann
SA, Ke Y and Hill AP: hERG K(+) channels: Structure, function, and
clinical significance. Physiol Rev. 92:1393–1478. 2012.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Pier DM, Shehatou GS, Giblett S, Pullar
CE, Trezise DJ, Pritchard CA, Challiss RA and Mitcheson JS:
Long-term channel block is required to inhibit cellular
transformation by human ether-à-go-go-related gene (hERG1)
potassium channels. Mol Pharmacol. 86:211–221. 2014.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Raschi E, Vasina V, Poluzzi E and De Ponti
F: The hERG K+ channel: Target and antitarget strategies in drug
development. Pharmacol Res. 57:181–195. 2008.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Stansfeld PJ, Sutcliffe MJ and Mitcheson
JS: Molecular mechanisms for drug interactions with hERG that cause
long QT syndrome. Expert Opin Drug Metab Toxicol. 2:81–94.
2006.PubMed/NCBI View Article : Google Scholar
|
|
60
|
He S, Moutaoufik MT, Islam S, Persad A, Wu
A, Aly KA, Fonge H, Babu M and Cayabyab FS: HERG channel and
cancer: A mechanistic review of carcinogenic processes and
therapeutic potential. Biochim Biophys Acta Rev Cancer.
1873(188355)2020.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Falk RH, Alexander KM, Liao R and Dorbala
S: AL (Light-Chain) cardiac amyloidosis: A review of diagnosis and
therapy. J Am Coll Cardiol. 68:1323–1341. 2016.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Gertz MA, Benson MD, Dyck PJ, Grogan M,
Coelho T, Cruz M, Berk JL, Plante-Bordeneuve V, Schmidt HHJ and
Merlini G: Diagnosis, prognosis, and therapy of transthyretin
amyloidosis. J Am Coll Cardiol. 66:2451–2466. 2015.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Brenner DA, Jain M, Pimentel DR, Wang B,
Connors LH, Skinner M, Apstein CS and Liao R: Human amyloidogenic
light chains directly impair cardiomyocyte function through an
increase in cellular oxidant stress. Circ Res. 94:1008–1010.
2004.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Sawyer DB, Siwik DA, Xiao L, Pimentel DR,
Singh K and Colucci WS: Role of oxidative stress in myocardial
hypertrophy and failure. J Mol Cell Cardiol. 34:379–388.
2002.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Lundin L, Norheim I, Landelius J, Oberg K
and Theodorsson-Norheim E: Carcinoid heart disease: Relationship of
circulating vasoactive substances to ultrasound-detectable cardiac
abnormalities. Circulation. 77:264–269. 1988.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Modlin IM and Sandor A: An analysis of
8305 cases of carcinoid tumors. Cancer. 79:813–829. 1997.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Hassan SA, Banchs J, Iliescu C, Dasari A,
Lopez-Mattei J and Yusuf SW: Carcinoid heart disease. Heart.
103:1488–1495. 2017.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Yeh ET, Tong AT, Lenihan DJ, Yusuf SW,
Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA and Ewer
MS: Cardiovascular complications of cancer therapy: Diagnosis,
pathogenesis, and management. Circulation. 109:3122–3131.
2004.PubMed/NCBI View Article : Google Scholar
|
|
69
|
McKenney AS and Levine RL: Isocitrate
dehydrogenase mutations in leukemia. J Clin Invest. 123:3672–3677.
2013.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Karlstaedt A, Zhang X, Vitrac H, Harmancey
R, Vasquez H, Wang JH, Goodell MA and Taegtmeyer H: Oncometabolite
d-2-hydroxyglutarate impairs α-ketoglutarate dehydrogenase and
contractile function in rodent heart. Proc Natl Acad Sci USA.
113:10436–10441. 2016.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Rinde LB, Småbrekke B, Hald EM, Brodin EE,
Njølstad I, Mathiesen EB, Løchen ML, Wilsgaard T, Brækkan SK, Vik A
and Hansen JB: Myocardial infarction and future risk of cancer in
the general population-the Tromsø study. Eur J Epidemiol.
32:193–201. 2017.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Berton G, Cordiano R, Cavuto F, Bagato F,
Segafredo B and Pasquinucci M: Neoplastic disease after acute
coronary syndrome: Incidence, duration, and features: The
ABC-4* study on heart disease. J Cardiovasc Med
(Hagerstown). 19:546–553. 2018.PubMed/NCBI View Article : Google Scholar
|
|
73
|
de Boer RA, Meijers WC, van der Meer P and
van Veldhuisen DJ: Cancer and heart disease: Associations and
relations. Eur J Heart Fail. 21:1515–1525. 2019.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Arab S, Gramolini AO, Ping P, Kislinger T,
Stanley B, van Eyk J, Ouzounian M, MacLennan DH, Emili A and Liu
PP: Cardiovascular proteomics: Tools to develop novel biomarkers
and potential applications. J Am Coll Cardiol. 48:1733–1741.
2006.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Isaac DL: Biomarkers in heart failure
management. Curr Opin Cardiol. 23:127–133. 2008.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Dewey CM, Spitler KM, Ponce JM, Hall DD
and Grueter CE: Cardiac-secreted factors as peripheral metabolic
regulators and potential disease biomarkers. J Am Heart Assoc.
5(e003101)2016.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Pavo N, Raderer M, Hülsmann M, Scheithauer
W, Adlbrecht C, Strunk G, Goliasch G, Gisslinger H, Steger GG,
Hejna M, et al: Cardiovascular biomarkers in patients with cancer
and their association with all-cause mortality. Heart.
101:1874–1880. 2015.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Tuñón J, Higueras J, Tarín N, Cristóbal C,
Lorenzo Ó, Blanco-Colio L, Martín-Ventura JL, Huelmos A, Alonso J,
Aceña Á, et al: N-terminal pro-brain natriuretic peptide is
associated with a future diagnosis of cancer in patients with
coronary artery disease. PLoS One. 10(e0126741)2015.PubMed/NCBI View Article : Google Scholar
|
|
79
|
de Boer RA, Daniels LB, Maisel AS and
Januzzi JL Jr: State of the Art: Newer biomarkers in heart failure.
Eur J Heart Fail. 17:559–569. 2015.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Hartupee J and Mann DL: Neurohormonal
activation in heart failure with reduced ejection fraction. Nat Rev
Cardiol. 14:30–38. 2017.PubMed/NCBI View Article : Google Scholar
|
|
81
|
George AJ, Thomas WG and Hannan RD: The
renin-angiotensin system and cancer: Old dog, new tricks. Nat Rev
Cancer. 10:745–759. 2010.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Ino K, Shibata K, Kajiyama H, Yamamoto E,
Nagasaka T, Nawa A, Nomura S and Kikkawa F: Angiotensin II type 1
receptor expression in ovarian cancer and its correlation with
tumour angiogenesis and patient survival. Br J Cancer. 94:552–560.
2006.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Catarata MJ, Ribeiro R, Oliveira MJ,
Robalo Cordeiro C and Medeiros R: Renin-angiotensin system in lung
tumor and microenvironment interactions. Cancers (Basel).
12(1457)2020.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Lever AF, Hole DJ, Gillis CR, McCallum IR,
McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL and
Robertson JW: Do inhibitors of angiotensin-I-converting enzyme
protect against risk of cancer? Lancet. 352:179–184.
1998.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Werner CM and Böhm M: The therapeutic role
of RAS blockade in chronic heart failure. Ther Adv Cardiovasc Dis.
2:167–177. 2008.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Reuter S, Gupta SC, Chaturvedi MM and
Aggarwal BB: Oxidative stress, inflammation, and cancer: How are
they linked? Free Radic Biol Med. 49:1603–1616. 2010.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Takimoto E and Kass DA: Role of oxidative
stress in cardiac hypertrophy and remodeling. Hypertension.
49:241–248. 2007.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Maiuri MC and Kroemer G: Essential role
for oxidative phosphorylation in cancer progression. Cell Metab.
21:11–12. 2015.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Diniz YS, Cicogna AC, Padovani CR, Silva
MD, Faine LA, Galhardi CM, Rodrigues HG and Novelli EL: Dietary
restriction and fibre supplementation: Oxidative stress and
metabolic shifting for cardiac health. Can J Physiol Pharmacol.
81:1042–1048. 2003.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Aune D, Chan DS, Greenwood DC, Vieira AR,
Rosenblatt DA, Vieira R and Norat T: Dietary fiber and breast
cancer risk: A systematic review and meta-analysis of prospective
studies. Ann Oncol. 23:1394–1402. 2012.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Lopaschuk GD, Ussher JR, Folmes CD, Jaswal
JS and Stanley WC: Myocardial fatty acid metabolism in health and
disease. Physiol Rev. 90:207–258. 2010.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Bonnet S, Archer SL, Allalunis-Turner J,
Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta
L, Bonnet S, et al: A mitochondria-K+ channel axis is suppressed in
cancer and its normalization promotes apoptosis and inhibits cancer
growth. Cancer Cell. 11:37–51. 2007.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Mann DL: Innate immunity and the failing
heart: The cytokine hypothesis revisited. Circ Res. 116:1254–1268.
2015.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Ridker PM, MacFadyen JG, Everett BM, Libby
P, Thuren T and Glynn RJ: CANTOS Trial Group. Relationship of
C-reactive protein reduction to cardiovascular event reduction
following treatment with canakinumab: A secondary analysis from the
CANTOS randomised controlled trial. Lancet. 391:319–328.
2018.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Ridker PM, MacFadyen JG, Thuren T, Everett
BM, Libby P and Glynn RJ: CANTOS Trial Group. Effect of
interleukin-1β inhibition with canakinumab on incident lung cancer
in patients with atherosclerosis: Exploratory results from a
randomised, double-blind, placebo-controlled trial. Lancet.
390:1833–1842. 2017.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Swann JB and Smyth MJ: Immune surveillance
of tumors. J Clin Invest. 117:1137–1146. 2007.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Zhang Y, Bauersachs J and Langer HF:
Immune mechanisms in heart failure. Eur J Heart Fail. 19:1379–1389.
2017.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Epelman S, Liu PP and Mann DL: Role of
innate and adaptive immune mechanisms in cardiac injury and repair.
Nat Rev Immunol. 15:117–129. 2015.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Frantz S, Falcao-Pires I, Balligand JL,
Bauersachs J, Brutsaert D, Ciccarelli M, Dawson D, de Windt LJ,
Giacca M, Hamdani N, et al: The innate immune system in chronic
cardiomyopathy: A European society of cardiology (ESC) scientific
statement from the working group on myocardial function of the ESC.
Eur J Heart Fail. 20:445–459. 2018.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Stakos DA, Kambas K, Konstantinidis T,
Mitroulis I, Apostolidou E, Arelaki S, Tsironidou V, Giatromanolaki
A, Skendros P, Konstantinides S and Ritis K: Expression of
functional tissue factor by neutrophil extracellular traps in
culprit artery of acute myocardial infarction. Eur Heart J.
36:1405–1414. 2015.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Frangogiannis NG, Smith CW and Entman ML:
The inflammatory response in myocardial infarction. Cardiovasc Res.
53:31–47. 2002.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Sun K, Li YY and Jin J: A double-edged
sword of immuno-microenvironment in cardiac homeostasis and injury
repair. Signal Transduct Target Ther. 6(79)2021.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Oktay AA, Rich JD and Shah SJ: The
emerging epidemic of heart failure with preserved ejection
fraction. Curr Heart Fail Rep. 10:401–410. 2013.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Pandya PH, Murray ME, Pollok KE and
Renbarger JL: The immune system in cancer pathogenesis: Potential
therapeutic approaches. J Immunol Res. 2016(4273943)2016.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Wei J, Galaviz KI, Kowalski AJ, Magee MJ,
Haw JS, Narayan KMV and Ali MK: Comparison of cardiovascular events
among users of different classes of antihypertension medications: A
systematic review and network meta-analysis. JAMA Netw Open.
3(e1921618)2020.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Sipahi I, Debanne SM, Rowland DY, Simon DI
and Fang JC: Angiotensin-receptor blockade and risk of cancer:
Meta-analysis of randomised controlled trials. Lancet Oncol.
11:627–636. 2010.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Bangalore S, Kumar S, Kjeldsen SE, Makani
H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C and
Messerli FH: Antihypertensive drugs and risk of cancer: Network
meta-analyses and trial sequential analyses of 324,168 participants
from randomised trials. Lancet Oncol. 12:65–82. 2011.PubMed/NCBI View Article : Google Scholar
|
|
108
|
ARB Trialists Collaboration. Effects of
telmisartan, irbesartan, valsartan, candesartan, and losartan on
cancers in 15 trials enrolling 138,769 individuals. J Hypertens.
29:623–635. 2011.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Chang CH, Lin JW, Wu LC and Lai MS:
Angiotensin receptor blockade and risk of cancer in type 2 diabetes
mellitus: A nationwide case-control study. J Clin Oncol.
29:3001–3007. 2011.PubMed/NCBI View Article : Google Scholar
|
|
110
|
McNeil JJ, Gibbs P, Orchard SG, Lockery
JE, Bernstein WB, Cao Y, Ford L, Haydon A, Kirpach B, Macrae F, et
al: Effect of aspirin on cancer incidence and mortality in older
adults. J Natl Cancer Inst. 113:258–265. 2021.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Falix FA, Aronson DC, Lamers WH and
Gaemers IC: Possible roles of DLK1 in the Notch pathway during
development and disease. Biochim Biophys Acta. 1822:988–995.
2012.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Rodriguez P, Sassi Y, Troncone L, Benard
L, Ishikawa K, Gordon RE, Lamas S, Laborda J, Hajjar RJ and Lebeche
D: Deletion of delta-like 1 homologue accelerates
fibroblast-myofibroblast differentiation and induces myocardial
fibrosis. Eur Heart J. 40:967–978. 2019.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Akiyama J, Okamoto R, Iwasaki M, Zheng X,
Yui S, Tsuchiya K, Nakamura T and Watanabe M: Delta-like 1
expression promotes goblet cell differentiation in
Notch-inactivated human colonic epithelial cells. Biochem Biophys
Res Commun. 393:662–667. 2010.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Wei Y, Shao J, Wang Y, Shen H, Yu S, Zhang
J and Yin L: Hsa-miR-370 inhibited P-selectin-induced cell adhesion
in human colon adenocarcinoma cells. Mol Cell Biochem. 450:159–166.
2019.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Wu XS, Wang XA, Wu WG, Hu YP, Li ML, Ding
Q, Weng H, Shu YJ, Liu TY, Jiang L, et al: MALAT1 promotes the
proliferation and metastasis of gallbladder cancer cells by
activating the ERK/MAPK pathway. Cancer Biol Ther. 15:806–814.
2014.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Liu JY, Yao J, Li XM, Song YC, Wang XQ, Li
YJ, Yan B and Jiang Q: Pathogenic role of lncRNA-MALAT1 in
endothelial cell dysfunction in diabetes mellitus. Cell Death Dis.
5(e1506)2014.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Gast M, Rauch BH, Nakagawa S, Haghikia A,
Jasina A, Haas J, Nath N, Jensen L, Stroux A, Böhm A, et al: Immune
system-mediated atherosclerosis caused by deficiency of long
non-coding RNA MALAT1 in ApoE-/-mice. Cardiovasc Res. 115:302–314.
2019.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Cremer S, Michalik KM, Fischer A,
Pfisterer L, Jaé N, Winter C, Boon RA, Muhly-Reinholz M, John D,
Uchida S, et al: Hematopoietic deficiency of the long noncoding RNA
MALAT1 promotes atherosclerosis and plaque inflammation.
Circulation. 139:1320–1334. 2019.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Li X, Li Y, Zhang T, Xiong X, Liu N, Pang
B, Ruan Y, Gao Y, Shang H and Xing Y: Role of cardioprotective
agents on chemotherapy-induced heart failure: A systematic review
and network meta-analysis of randomized controlled trials.
Pharmacol Res. 151(104577)2020.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Totzeck M, Mincu RI, Heusch G and Rassaf
T: Heart failure from cancer therapy: Can we prevent it? ESC Heart
Fail. 6:856–862. 2019.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Kollárová-Brázdová P, Jirkovská A,
Karabanovich G, Pokorná Z, Bavlovič Piskáčková H, Jirkovský E,
Kubeš J, Lenčová-Popelová O, Mazurová Y, Adamcová M, et al:
Investigation of structure-activity relationships of dexrazoxane
analogs reveals topoisomerase IIβ interaction as a prerequisite for
effective protection against anthracycline cardiotoxicity. J
Pharmacol Exp Ther. 373:402–415. 2020.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Chang WT, Lin YW, Ho CH, Chen ZC, Liu PY
and Shih JY: Dapagliflozin suppresses ER stress and protects
doxorubicin-induced cardiotoxicity in breast cancer patients. Arch
Toxicol. 95:659–671. 2021.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Fitzgerald MD, Tanaka H, Tran ZV and Seals
DR: Age-related declines in maximal aerobic capacity in regularly
exercising vs sedentary women: A meta-analysis. J Appl Physiol
(1985). 83:160–165. 1997.PubMed/NCBI View Article : Google Scholar
|
|
124
|
MacVicar MG, Winningham ML and Nickel JL:
Effects of aerobic interval training on cancer patients' functional
capacity. Nurs Res. 38:348–351. 1989.PubMed/NCBI
|
|
125
|
Jones LW, Fels DR, West M, Allen JD,
Broadwater G, Barry WT, Wilke LG, Masko E, Douglas PS, Dash RC, et
al: Modulation of circulating angiogenic factors and tumor biology
by aerobic training in breast cancer patients receiving neoadjuvant
chemotherapy. Cancer Prev Res (Phila). 6:925–937. 2013.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Courneya KS, Sellar CM, Stevinson C,
McNeely ML, Peddle CJ, Friedenreich CM, Tankel K, Basi S, Chua N,
Mazurek A and Reiman T: Randomized controlled trial of the effects
of aerobic exercise on physical functioning and quality of life in
lymphoma patients. J Clin Oncol. 27:4605–4612. 2009.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Jones LW, Douglas PS, Khouri MG, Mackey
JR, Wojdyla D, Kraus WE, Whellan DJ and O'Connor CM: Safety and
efficacy of aerobic training in patients with cancer who have heart
failure: An analysis of the HF-ACTION randomized trial. J Clin
Oncol. 32:2496–2502. 2014.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Hughes DC, Lenihan DJ, Harrison CA and
Basen-Engquist KM: Exercise intervention for cancer survivors with
heart failure: Two case reports. J Exerc Sci Fit. 9:65–73.
2011.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Maginador G, Lixandrão ME, Bortolozo HI,
Vechin FC, Sarian LO, Derchain S, Telles GD, Zopf E, Ugrinowitsch C
and Conceição MS: Aerobic exercise-induced changes in
cardiorespiratory fitness in breast cancer patients receiving
chemotherapy: A systematic review and meta-analysis. Cancers
(Basel). 12(2240)2020.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Rochette L, Meloux A, Zeller M, Cottin Y
and Vergely C: Role of humanin, a mitochondrial-derived peptide, in
cardiovascular disorders. Arch Cardiovasc Dis. 113:564–571.
2020.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Cai H, Liu Y, Men H and Zheng Y:
Protective mechanism of humanin against oxidative stress in
aging-related cardiovascular diseases. Front Endocrinol (Lausanne).
12(683151)2021.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Thummasorn S, Shinlapawittayatorn K,
Khamseekaew J, Jaiwongkam T, Chattipakorn SC and Chattipakorn N:
Humanin directly protects cardiac mitochondria against dysfunction
initiated by oxidative stress by decreasing complex I activity.
Mitochondrion. 38:31–40. 2018.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Qin Q, Mehta H, Yen K, Navarrete G,
Brandhorst S, Wan J, Delrio S, Zhang X, Lerman LO, Cohen P and
Lerman A: Chronic treatment with the mitochondrial peptide humanin
prevents age-related myocardial fibrosis in mice. Am J Physiol
Heart Circ Physiol. 315:H1127–H1136. 2018.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Lue Y, Swerdloff R, Wan J, Xiao J, French
S, Atienza V, Canela V, Bruhn KW, Stone B, Jia Y, et al: The potent
humanin analogue (HNG) protects germ cells and leucocytes while
enhancing chemotherapy-induced suppression of cancer metastases in
male mice. Endocrinology. 156:4511–4521. 2015.PubMed/NCBI View Article : Google Scholar
|
